Epirubicin for the Treatment of Sepsis & Septic Shock
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety of low doses of epirubicin in sepsis patients. Therefore the
study will look for side effects in patients treated with low dose epirubicin compared to
control patients.
In animals, low dose epirubicin has been shown to induce tolerance to infection and increase
survival in septic mice.
The study will also look for positive effects on organ function in humans. The investigators
hypothesize that low-dose epirubicin can be used therapeutically to improve the disease
course and lessen mortality of patients with sepsis. In a first step, the investigators aim
at proving that low-dose epirubicin can safely be administered to sepsis patients and will
perform a dose-escalation multi-center trial.
Phase:
Phase 2
Details
Lead Sponsor:
Jena University Hospital
Collaborators:
Ruhr University of Bochum University Medicine Greifswald